We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-15.04%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$185M
AUM Growth
-$43.2M
Cap. Flow
+$19.8M
Cap. Flow %
10.73%
Top 10 Hldgs %
66.67%
Holding
76
New
13
Increased
20
Reduced
16
Closed
22

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$9.46M
2
ZGNX
Zogenix, Inc.
ZGNX
+$5.9M
3
RCM
R1 RCM Inc. Common Stock
RCM
+$5.74M
4
AERI
Aerie Pharmaceuticals
AERI
+$5.26M
5
AMRN
Amarin Corp
AMRN
+$4.88M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$7.55M
2
SAGE
Sage Therapeutics
SAGE
+$4.05M
3
ABT icon
Abbott
ABT
+$3.07M
4
MDT icon
Medtronic
MDT
+$2.65M
5
ANAB icon
AnaptysBio
ANAB
+$2.25M

Sector Composition

Rank Sector Weight
1 Healthcare 87.02%
2 Industrials 10.11%
3 Miscellaneous 2.35%
4 Real Estate 0.52%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
1
DELISTED
Zogenix, Inc.
ZGNX
$20.5M 11.12%
563,429
+144,150
+34% +$5.9M
GSK icon
2
GSK
GSK
$102B
$20.4M 11.04%
423,587
+192,160
+83% +$9.46M
RCM
3
DELISTED
R1 RCM Inc. Common Stock
RCM
$18.7M 10.11%
2,349,306
+664,219
+39% +$5.74M
AMRN
4
Amarin Corp
AMRN
$295M
$17.2M 9.31%
63,170
+13,385
+27% +$4.88M
SNY icon
5
Sanofi
SNY
$107B
$13.3M 7.2%
306,242
+25,370
+9% +$1.12M
RDUS
6
DELISTED
Radius Health, Inc.
RDUS
$9.1M 4.93%
552,053
+23,061
+4% +$388K
AERI
7
DELISTED
Aerie Pharmaceuticals
AERI
$8.4M 4.55%
232,790
+112,079
+93% +$5.26M
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$137B
$6.05M 3.27%
36,492
-11,600
-24% -$2.01M
DHR icon
9
Danaher
DHR
$152B
$4.94M 2.67%
53,923
+13,762
+34% +$1.25M
ABMD
10
DELISTED
Abiomed Inc
ABMD
$4.53M 2.45%
13,939
+10,520
+308% +$3.65M
SRPT icon
11
Sarepta Therapeutics
SRPT
$2.2B
$4.42M 2.39%
40,494
-1,700
-4% -$213K
VTRS icon
12
CALL
Viatris
VTRS
$18.8B
$4.35M 2.35%
+158,600
New +$5.14M
ARGX icon
13
argenx
ARGX
$64B
$3.67M 1.99%
38,224
+14,670
+62% +$1.3M
MRK icon
14
Merck
MRK
$366B
$3.53M 1.91%
47,998
-106,896
-69% -$7.55M
ENSG icon
15
The Ensign Group
ENSG
$10.1B
$3.32M 1.8%
91,480
-52,466
-36% -$2.04M
ARNA
16
DELISTED
Arena Pharmaceuticals Inc
ARNA
$3.17M 1.72%
81,371
-38,000
-32% -$1.49M
TLGT
17
DELISTED
Teligent, Inc
TLGT
$3.08M 1.67%
224,748
+13,538
+6% +$354K
TSRO
18
DELISTED
TESARO, Inc.
TSRO
$2.67M 1.45%
+36,000
New +$1.73M
ABT icon
19
Abbott
ABT
$195B
$2.27M 1.23%
31,400
-43,700
-58% -$3.07M
FATE icon
20
Fate Therapeutics
FATE
$291M
$2.12M 1.15%
+165,000
New +$2.3M
QGEN icon
21
Qiagen
QGEN
$8.9B
$1.91M 1.03%
+52,151
New +$1.94M
ILMN icon
22
Illumina
ILMN
$32.6B
$1.54M 0.84%
+5,292
New +$1.64M
GHDX
23
DELISTED
Genomic Health, Inc.
GHDX
$1.54M 0.83%
+23,866
New +$1.67M
VTRS icon
24
Viatris
VTRS
$18.8B
$1.51M 0.82%
+55,000
New +$1.78M
DCPH
25
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$1.46M 0.79%
+69,700
New +$1.71M
1
2 3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q4 2018 Portfolio in Review

As of Q4 2018, Eversept Partners held 76 positions worth $185M, down 19% from $228M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Eversept Partners deployed $19.8M of net new capital in Q4 2018, opening 13 new positions and adding to 20 existing holdings. Its largest new stake was Fate Therapeutics: 165,000 shares worth $2.12M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 79% a quarter earlier, followed by Industrials and Miscellaneous.

On the sell side, the largest reduction was Merck, an estimated $7.55M trimmed.

  • Eversept Partners's largest Q4 2018 buy was Fate Therapeutics: 165,000 shares worth $2.12M.
  • Eversept Partners added most to GSK in Q4 2018, an estimated $9.46M increase.
  • Eversept Partners's biggest Q4 2018 reduction was Merck, cutting an estimated $7.55M.
  • Eversept Partners fully exited Medtronic in Q4 2018, selling an estimated $2.65M.
  • Eversept Partners's ten largest holdings make up 67% of its $185M portfolio in Q4 2018.
  • Eversept Partners opened 13 new positions and closed 22 in Q4 2018.
  • Eversept Partners's portfolio value fell 19% quarter-over-quarter to $185M.

Based on Eversept Partners's 13F filing for Q4 2018, filed 13 Feb 2019.